LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

LY2495655, an antimyostatin antibody, in pancreatic cancer: a randomized, phase 2 trial

Abstract Background Cachexia is a formidable clinical challenge in pancreatic cancer. We assessed LY2495655 (antimyostatin antibody) plus standard‐of‐care chemotherapy in pancreatic cancer using cachexia status as a stratifier. Methods In this randomized, phase 2 trial, patients with stage II–IV pan...

Full description

Bibliographic Details
Main Authors: Talia Golan, Ravit Geva, Donald Richards, Srinivasan Madhusudan, Boris Kin Lin, Haofei Tiffany Wang, Richard A. Walgren, Salomon M. Stemmer
Format: Article
Language:English
Published: Wiley 2018-10-01
Series:Journal of Cachexia, Sarcopenia and Muscle
Subjects:
Myostatin
Cachexia
Pancreatic cancer
Muscle mass
Online Access:https://doi.org/10.1002/jcsm.12331

Internet

https://doi.org/10.1002/jcsm.12331

Similar Items